Nanotechnology Now - News Story: U.S. Lead in Nanotechnology Depends on Growth of FDA and Gov’t Initiatives: European revenue from nanotech-enabled products is projected to surpass that of the U.S. by 2015, according to Lux Research

Home > News > U.S. Lead in Nanotechnology Depends on Growth of FDA and Gov’t Initiatives: European revenue from nanotech-enabled products is projected to surpass that of the U.S. by 2015, according to Lux Research

December 14th, 2011

U.S. Lead in Nanotechnology Depends on Growth of FDA and Gov’t Initiatives: European revenue from nanotech-enabled products is projected to surpass that of the U.S. by 2015, according to Lux Research

Abstract:
The recently enacted spending bill, which covered FDA, contained some good news for proponents of nanotechnology as well as the promise of more to come in years ahead. The latter will be harder to deliver considering the overall budget constraints of the U.S. Making good on the promise, however, is likely key to the country's ability to at least retain its number one position in nanotechnology if not expand this lead.

FDA's National Center for Toxicological Research (NCTR) was approved $60 million for fiscal 2012, which was proposed by President Barack Obama and favored over the $51.5 million sought by the Republican-controlled House of Representatives. While NCTR's latest approved budget did not increase compared to fiscal year 2011, at least it did not go down. NCTR's duties include conducting peer-reviewed research to identify health and safety issues related to new medical products like nanomaterials.

Source:
genengnews.com

Bookmark: